69 related articles for article (PubMed ID: 35085002)
1. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract][Full Text] [Related]
2. Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles With PSMA-11 Peptides: A Preclinical Study.
Ghorbani F; Aminzadeh B; Borji N; Soudmand S; Montazerabadi A
J Magn Reson Imaging; 2024 Jun; 59(6):2204-2214. PubMed ID: 37572082
[TBL] [Abstract][Full Text] [Related]
3. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
[TBL] [Abstract][Full Text] [Related]
4. Precise prostate cancer diagnosis using fluorescent nanoprobes for detecting PSA and PSMA in serum.
Ouyang M; Jia M; Chang Z; Wang Y; Wang K; Gao X; Tang B
Chem Commun (Camb); 2024 May; 60(39):5181-5184. PubMed ID: 38647078
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma.
Mackay S; Oduor IO; Burch TC; Troyer DA; Semmes OJ; Nyalwidhe JO
Prostate; 2024 Apr; 84(5):479-490. PubMed ID: 38151791
[TBL] [Abstract][Full Text] [Related]
6. PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer.
Palamiuc L; Emerling BM
J Exp Med; 2018 Jan; 215(1):17-19. PubMed ID: 29222106
[TBL] [Abstract][Full Text] [Related]
7. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021).
S V; N N; Kurmi BD; Das Gupta G; Verma SK; Jain A; Patel P
Anticancer Agents Med Chem; 2024 Jan; ():. PubMed ID: 38288815
[TBL] [Abstract][Full Text] [Related]
8. First-in-human study of PSMA-targeting agent, [
Zhao R; Ke M; Lv J; Liu S; Liu Y; Zhang J; Xu L; Gu D; Li M; Cai C; Liu Y; Zeng G; Alexoff D; Ploessl K; Zhu L; Kung HF; Wang X
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1753-1762. PubMed ID: 38212531
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
[TBL] [Abstract][Full Text] [Related]
10. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging.
Topoozian M; Calais J; Felker E; Sisk A; Gonzalez S; Lee SJ; Marks LS
Urol Case Rep; 2023 Sep; 50():102461. PubMed ID: 37358989
[TBL] [Abstract][Full Text] [Related]
11. The most effective but largely ignored target for prostate cancer early detection and intervention.
Man YG; Mannion C; Jewett A; Hsiao YH; Liu A; Semczuk A; Zarogoulidis P; Gapeev AB; Cimadamore A; Lee P; Lopez-Beltran A; Montironi R; Massari F; Lu X; Cheng L
J Cancer; 2022; 13(13):3463-3475. PubMed ID: 36313040
[TBL] [Abstract][Full Text] [Related]
12.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
16. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen.
Kuppermann D; Calais J; Marks LS
J Urol; 2022 Apr; 207(4):769-778. PubMed ID: 35085002
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
